Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
- NEWS RELEASE
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients.
For detailed information, see the below URL.
CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAM™ mouse model was published in JHEP Reports (A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage - JHEP Reports (jhep-reports.eu)
In the future, we believe that further clinical trial results for CM-101 will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.